Weighing the GLP-1 Market
Goldman Sachs Exchanges
Medicare Coverage Discrepancy for GLP-1 Medications
Exploring the disparities in insurance coverage for GLP-1 medications for obesity treatment, particularly focusing on the lack of Medicare coverage compared to diabetes medications. The chapter analyzes the potential costs and implications of expanding Medicare coverage for these drugs in the US.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
